出典:Wikipedia
出典:『Wikipedia』 (2011/06/30 23:07 UTC 版)
Ivacaftor (VX-770) is an experimental drug candidate for the treatment of cystic fibrosis, currently under development by Vertex Pharmaceuticals and the Cystic Fibrosis Foundation. The drug is designed to be effective in patients that have the G551D mutation in the defective protein that causes the disease. The drug is currently in Phase 3 clinical trials and has showed promising results for this subset of cystic fibrosis patients.